Jiangsu Hengrui Medicine Co., Ltd. (HKG:1276)
Hong Kong · Delayed Price · Currency is HKD 75.20
+2.60 (3.58%)
At close: Oct 31, 2025
Jiangsu Hengrui Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 7,468 | 6,337 | 4,302 | 3,906 | 4,530 | 6,328 | Upgrade |
Depreciation & Amortization | 772.2 | 772.2 | 704.64 | 577.89 | 520.41 | 448.39 | Upgrade |
Other Amortization | 98.62 | 98.62 | 89.3 | 66.26 | 20.33 | 27.27 | Upgrade |
Loss (Gain) From Sale of Assets | -5.4 | -5.4 | -3.16 | -5.47 | -3.37 | -2.98 | Upgrade |
Asset Writedown & Restructuring Costs | 4.94 | 4.94 | 76.21 | 131.24 | -117.52 | -19.02 | Upgrade |
Loss (Gain) From Sale of Investments | -132.5 | -132.5 | 35.62 | -533.84 | -169.57 | -339.96 | Upgrade |
Provision & Write-off of Bad Debts | -28.67 | -28.67 | -15.77 | 26.02 | -3.87 | 9.36 | Upgrade |
Other Operating Activities | 3,424 | 30.83 | 17.02 | -67.79 | -27.8 | -14.88 | Upgrade |
Change in Accounts Receivable | -375.7 | -375.7 | 2,036 | -2,285 | -868.27 | -3,486 | Upgrade |
Change in Inventory | -135.63 | -135.63 | 129.11 | -52.68 | -631.22 | -173.62 | Upgrade |
Change in Accounts Payable | 671.41 | 671.41 | 315.32 | -511.05 | 809.7 | 222.12 | Upgrade |
Change in Other Net Operating Assets | 209.26 | 209.26 | 55.47 | 34.98 | 253.16 | 414.48 | Upgrade |
Operating Cash Flow | 11,948 | 7,423 | 7,644 | 1,265 | 4,219 | 3,432 | Upgrade |
Operating Cash Flow Growth | 50.85% | -2.89% | 504.12% | -70.01% | 22.93% | -10.08% | Upgrade |
Capital Expenditures | -2,159 | -1,969 | -1,484 | -1,992 | -1,665 | -554.33 | Upgrade |
Sale of Property, Plant & Equipment | 20.87 | 21.9 | 20.18 | 20.21 | 16.11 | 3.56 | Upgrade |
Divestitures | - | - | - | 36.05 | - | - | Upgrade |
Investment in Securities | 533.8 | -17.2 | 2,590 | 2,160 | 842.49 | 2,007 | Upgrade |
Other Investing Activities | 39.52 | 52.51 | 95.51 | 166.49 | 259.77 | 341.42 | Upgrade |
Investing Cash Flow | -1,565 | -1,912 | 1,222 | 390.29 | -546.26 | 1,798 | Upgrade |
Short-Term Debt Issued | - | - | - | 1,260 | - | - | Upgrade |
Long-Term Debt Issued | - | 799.91 | 21.1 | - | - | - | Upgrade |
Total Debt Issued | 428.34 | 799.91 | 21.1 | 1,260 | - | - | Upgrade |
Long-Term Debt Repaid | - | -847.28 | -1,315 | -36.28 | -31.05 | - | Upgrade |
Net Debt Issued (Repaid) | 380.96 | -47.38 | -1,294 | 1,224 | -31.05 | - | Upgrade |
Issuance of Common Stock | 10,352 | - | - | - | - | 1,171 | Upgrade |
Repurchase of Common Stock | -228.43 | -228.43 | -827.26 | -1,066 | -235.16 | -11.98 | Upgrade |
Common Dividends Paid | -1,274 | -1,275 | -1,023 | -1,016 | -1,066 | -1,017 | Upgrade |
Other Financing Activities | -1,183 | - | - | 538.86 | 334.14 | 149.1 | Upgrade |
Financing Cash Flow | 8,047 | -1,551 | -3,144 | -318.77 | -998.32 | 291.19 | Upgrade |
Foreign Exchange Rate Adjustments | -117.96 | 7.4 | 12.53 | 80.5 | -16.87 | -89.08 | Upgrade |
Net Cash Flow | 18,312 | 3,968 | 5,734 | 1,417 | 2,657 | 5,432 | Upgrade |
Free Cash Flow | 9,789 | 5,454 | 6,160 | -726.91 | 2,554 | 2,878 | Upgrade |
Free Cash Flow Growth | 55.82% | -11.47% | - | - | -11.24% | -11.61% | Upgrade |
Free Cash Flow Margin | 31.59% | 19.49% | 26.99% | -3.42% | 9.86% | 10.38% | Upgrade |
Free Cash Flow Per Share | 1.52 | 0.86 | 0.97 | -0.11 | 0.40 | 0.45 | Upgrade |
Cash Income Tax Paid | 2,477 | 2,290 | 1,568 | 1,631 | 1,607 | 3,022 | Upgrade |
Levered Free Cash Flow | 8,450 | 4,410 | 4,866 | -2,030 | 1,151 | 2,583 | Upgrade |
Unlevered Free Cash Flow | 8,459 | 4,414 | 4,869 | -2,026 | 1,154 | 2,583 | Upgrade |
Change in Working Capital | 346.19 | 346.19 | 2,437 | -2,835 | -530.01 | -3,005 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.